Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

There is an urgent need to develop treatments for patients with melanoma who are refractory to or ineligible for immune checkpoint blockade, including patients who lack BRAF-V600E/K mutations. This is often the case in patients diagnosed with rare melanoma subtypes such as mucosal and acral melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Nabanita, Amato, Carol M., Skees, Jenette, Todd, Kaleb J., Lambert, Karoline A., Robinson, William A., Van Gulick, Robert, Weight, Ryan M., Dart, Chiara R., Tobin, Richard P., McCarter, Martin D., Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464298/
https://www.ncbi.nlm.nih.gov/pubmed/32764384
http://dx.doi.org/10.3390/cancers12082182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464298/
https://www.ncbi.nlm.nih.gov/pubmed/32764384
http://dx.doi.org/10.3390/cancers12082182

Ejemplares similares